Understand local therapy and the immune system
Explain what local treatment can control, how immune learning might follow and what evidence supports an added clinical benefit.
Local treatment can have an important job at a particular site. A second idea is more uncertain: could injury at that site help the immune system recognize cancer elsewhere? This guide gives you the language to keep those questions separate while reading a study or discussing a proposal.
You do not need to choose a treatment to follow the course. Start with the mechanism, carry the disease setting into the evidence, then practice inspecting a proposal and its measurements.
The big ideas
- Local control, immune activity, a distant response and improvement in patient outcomes are different claims.
- T-cell priming needs more than released tumor material. Recognition and access remain important even after an immune response begins.
- A trial result belongs to its cancer population, disease history, comparison and endpoint. Positive lung-cancer findings do not establish an added breast-cancer benefit.
- Delivery matters. A probe, externally aimed beams and a radioactive drug distributed through the blood do not provide the same exposure or risks.
The map
Follow the arrows as a reading order, rather than as a clinical decision algorithm.
Each lesson adds a question to carry into the next one. Open a lesson from the linked table below.
Lessons
| Step | Lesson | Question it answers | Minutes | Learning aid |
|---|---|---|---|---|
| 1 | Separate local injury from immune learning | Which immune gates remain after a tumor is injured? | 12 | A fictional treated-site and distant-site example |
| 2 | Put the disease setting before the clock | What job is the treatment meant to do? | 12 | Three fictional treatment-setting cards |
| 3 | Ask what a combination trial actually proved | Does the cited comparison support this claim? | 16 | Four real study cards and a fictional attribution exercise |
| 4 | Read a proposal through five questions | Which assumptions need evidence or planning? | 12 | A diameter shortcut and an uptake claim |
| 5 | Match each measurement to its claim | What did this sample or scan actually measure? | 14 | A worked percentage-and-denominator example |
| 6 | Compare delivery and recognition separately | How do different tools direct exposure and produce effects? | 14 | Three fictional “targeted” proposals and a capstone |
The full path is about 80 minutes, including practice. If you are reading one proposal today, lesson 4 can help organize your questions; use its prerequisite links to fill in the earlier steps.
Concepts you will use
The cancer-immunity cycle, human leukocyte antigen (HLA) and cross-presentation explain the immune gates. Immunogenic cell death, in-situ vaccination and the abscopal effect name distinct parts of the local-to-distant hypothesis.
For the physical tools, use ablation, radiation therapy, stereotactic body radiation therapy and hypofractionation. Survival endpoints and randomization help you judge outcome claims.
Applied to Diana
Read these lessons alongside the care plan and the local-treatment and abscopal question. Those pages own the case application and current decisions. This guide supplies a reusable way to inspect their evidence.
What remains uncertain
A plausible immune mechanism does not tell us which person will benefit, which sequence is best, or whether an added procedure improves survival. Sampling can reveal one step while leaving others unmeasured. A useful reading result may be a clearly stated missing comparison.
After the course, use the local-treatment reference shelf to find sources by question. Continue with reading cancer evidence for more practice with endpoints and uncertainty, or understanding early breast-cancer treatment sequencing for established local and systemic roles in that setting.
Sources and scope
Source check: 2026-10-09. General education; all named practice patients are fictional. Expert and learner review pending. Each lesson identifies the sources supporting its specific claims.
- National Cancer Institute: radiation therapy — treatment goals and physical exposure.
- Galluzzi et al., 2020: immunogenic cell death guidance — signals, immune responses and measurement boundaries.
- Chmura et al., 2026: NRG-BR002 — a breast-cancer-specific comparison of adding metastasis-directed treatment.